RTW funds disclose 8.1% Protagonist Therapeutics (PTGX) ownership stake
Rhea-AI Filing Summary
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,059,053 shares of Protagonist Therapeutics common stock, representing 8.1% of the class. This percentage is based on 62,515,666 shares outstanding as of October 29, 2025, as disclosed in the company’s Form 10-Q.
The shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist Therapeutics.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Protagonist Therapeutics (PTGX) does RTW Investments’ stake represent?
The filing states an 8.1% beneficial ownership of Protagonist Therapeutics’ common stock. This percentage is calculated using 62,515,666 shares outstanding as of October 29, 2025, as reported in the company’s Form 10-Q filed on November 6, 2025.
Who are the reporting persons in this Protagonist Therapeutics (PTGX) Schedule 13G/A?
The reporting persons are RTW Investments, LP, a Delaware investment adviser, and Roderick Wong, M.D., its Managing Partner and Chief Investment Officer. Both report shared voting and dispositive power over the same 5,059,053 Protagonist Therapeutics shares.
On what date is the Protagonist Therapeutics (PTGX) ownership information in this Schedule 13G/A effective?
The event date requiring this Schedule 13G/A filing is December 31, 2025. The ownership percentages are calculated using shares outstanding as of October 29, 2025, based on Protagonist Therapeutics’ Form 10-Q filed November 6, 2025.
Do RTW Investments and Roderick Wong seek to influence control of Protagonist Therapeutics (PTGX)?
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Protagonist Therapeutics, consistent with a Schedule 13G passive ownership filing framework.